Recent Updates
Recently added Catalysts

Eloralintide

Phase 3

Obesity | Small molecule | Metabolic |Eli Lilly and Company|Last Updated: Jun 4, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment2,010
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07321886A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesPHASE3 RECRUITING 1,980 — — Feb 6, 2026Jul 1, 2030Jun 4, 2026169 United States, Argentina +13
NCT06916091A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightPHASE1 COMPLETED 30 — — Apr 21, 2025Sep 9, 2025Nov 19, 20251 Singapore
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Change from Baseline in Body Weight
Baseline, Week 64
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline to Study Completion (Up to 10 Weeks)

A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary Endpoints
Percent Change from Baseline in Total Body Fat Mass
Baseline, Week 64
Change from Baseline in Waist Circumference
Baseline, Week 64
Percent Change from Baseline in Triglycerides
Baseline, Week 64
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Eloralintide Dose 1EXPERIMENTALParticipants will receive eloralintide subcutaneously (SC)
Eloralintide Dose 2EXPERIMENTALParticipants will receive eloralintide SC
Eloralintide Dose 3EXPERIMENTALParticipants will receive eloralintide SC
Eloralintide Dose 4EXPERIMENTALParticipants will receive eloralintide SC
PlaceboPLACEBO_COMPARATORParticipants will receive placebo SC
EloralintideEXPERIMENTALEloralintide administered subcutaneously (SC)
Interventions
NameTypeDescription
EloralintideDRUGAdministered SC
PlaceboDRUGAdministered SC
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites169

Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or...

Countries:United StatesArgentinaAustraliaBelgiumBrazilCanadaChinaGermanyIndiaJapanPolandPuerto RicoSouth KoreaTaiwanUnited KingdomSingapore
Unlock Eligibility Criteria
Competitive Landscape -Obesity 202 trials
CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY43PHASE3Retatrutide, Orforglipron, Tirzepatide, Ixekizumab, Eloralintide
Amgen Inc.AMGN10PHASE3Maridebart cafraglutide, Maridebart Cafraglutide, Moxifloxacin, COC
Novo Nordisk A/S Sponsored ADR Class BNVO47PHASE3Cagrilintide, Semaglutide, Liraglutide, CagriSema, NNC0487-0111
Rhythm Pharmaceuticals, Inc.RYTM8PHASE3Setmelanotide, Bivamelagon, Part C: RM-718, Part D: RM-718
Pfizer Inc.PFE2PHASE3PF-08653944
Regeneron Pharmaceuticals, Inc.REGN3PHASE3Mibavademab, Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
AstraZeneca PLCAZN3PHASE2AZD6234, AZD9550, Plocebo
Kailera Therapeutics, Inc.KLRA4PHASE3KAI-9531, Semaglutide, KAI-7535
Structure Therapeutics, Inc. Sponsored ADRGPCR3PHASE2Aleniglipron
PfizerMTSR3PHASE3MET097, MET233 and MET097
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab, semaglutide
Palatin Technologies, IncPTN1PHASE2bremelanotide, tirzepatide
Veru IncVERU1PHASE2Enobosarm, Semaglutide weekly
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE1ARO-INHBE, Tirzepatide, ARO-ALK7
Alnylam Pharmaceuticals, IncALNY1PHASE1ALN-2232, Tirzepatide
Gilead Sciences, Inc.GILD1PHASE1GS-4571, Omeprazole
AbbVie, Inc.ABBV1PHASE1ABBV-295
MBX Biosciences, Inc.MBX1PHASE1MBX 4291
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 4, 2026NCT07321886lastUpdatePostDate: changed
LOWJun 4, 2026NCT07321886lastUpdatePostDate: changed
LOWJun 4, 2026NCT07321886lastUpdatePostDate: changed
LOWJun 4, 2026NCT07321886lastUpdatePostDate: changed
LOWMay 26, 2026NCT07321886primaryCompletionDate: changed
LOWMay 24, 2026NCT07321886studyFirstPostDate: changed